What You Should Know:
– COTA, Inc., a healthcare technology company that uses real-world data to bring clarity to cancer care, has secured $34M in funding.
– Access to over one million patient data records and additional funding support enhanced real-world data and analytics services in oncology.
COTA, Inc., a Boston, MA-based healthcare technology company that uses real-world data to bring clarity to cancer care, today announced it has raised $34 million in Series D funding led by Baptist Health South Florida and ONC Capital with participation from EW Healthcare, Horizon BCBS and other existing investors. This also includes a $20M investment from Varian, who negotiated an option to acquire COTA at a later date.
Bringing Clarity to Cancer
COTA was founded in 2011 by a team of doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real-world data. The company organizes fragmented, often hidden data from the real world to provide clarity in cancer care. Combining clinical expertise in cancer with proprietary technology and advanced analytics, COTA’s platform helps inform decisions and action in oncology. COTA partners with providers, payers, and life science companies to ensure that everyone touched by cancer has a clear path to the right care.
COTA offerings include:
Providers: Curate EHR data that can be used to drive research and standardization in order to improve patient outcomes while also reducing costs at your institution.
Payers: Make clinical sense of claims data, providing insight into performance and related outcomes across sites in order to support value-based payment models.
Life Sciences: Deeplycurated real-world data accelerates drug development informing the decisions and actions that will deliver the best drugs to patients faster and at a lower cost.
The company will use the latest round of funding to expand its data access by over 300%, which now well exceeds one million oncology patient records. This growth will support the company’s commitment to accelerating the use of real-world data to improve patient outcomes and increase efficiency in oncology drug development. data helps life science partners answer key research questions, and in 2020 alone, COTA is projected to double its life science customers, growing from 8 to 16.
“COTA is proud to receive this validation from leading institutions across the oncology ecosystem.” said Michael Doyle, President and CEO of COTA. “The additional capital combined with our increased data access positions COTA for tremendous growth and enables us to drive innovation in oncology using real-world data. Our high-quality data and technology solutions will improve how cancer is treated and provide much needed clarity to patients as they navigate their cancer journey.”